HAMLET B Stock Overview
Engages in the development of drugs for the treatment and prevention of cancer in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Hamlet BioPharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.62 |
| 52 Week High | SEK 5.02 |
| 52 Week Low | SEK 1.00 |
| Beta | 1.12 |
| 11 Month Change | -34.50% |
| 3 Month Change | -24.06% |
| 1 Year Change | 85.16% |
| 33 Year Change | -61.24% |
| 5 Year Change | -80.00% |
| Change since IPO | 12.29% |
Recent News & Updates
Recent updates
Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?
Jul 04
Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation
Mar 04We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth
Nov 10We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth
Jun 17Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth
Oct 12Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?
Mar 17Shareholder Returns
| HAMLET B | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -8.4% | -0.5% | -0.2% |
| 1Y | 85.2% | 14.3% | 11.8% |
Return vs Industry: HAMLET B exceeded the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: HAMLET B exceeded the Swedish Market which returned 11.8% over the past year.
Price Volatility
| HAMLET B volatility | |
|---|---|
| HAMLET B Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: HAMLET B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: HAMLET B's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 8 | Petter Lindqvist | www.hamletpharma.com |
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company’s products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer.
Hamlet BioPharma AB (publ) Fundamentals Summary
| HAMLET B fundamental statistics | |
|---|---|
| Market cap | SEK 439.54m |
| Earnings (TTM) | -SEK 43.25m |
| Revenue (TTM) | n/a |
9,999x
P/S Ratio-10.2x
P/E RatioIs HAMLET B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HAMLET B income statement (TTM) | |
|---|---|
| Revenue | -SEK 8.51k |
| Cost of Revenue | SEK 0 |
| Gross Profit | -SEK 8.51k |
| Other Expenses | SEK 43.24m |
| Earnings | -SEK 43.25m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Nov 25, 2024
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 100.00% |
| Net Profit Margin | 508,198.31% |
| Debt/Equity Ratio | 0% |
How did HAMLET B perform over the long term?
See historical performance and comparison